| Abstrakt: |
This is an observational case-control study. It was carried out at the dermatology outpatient clinic in Al Fayha'a teaching hospital during the period from November 2020 to June 2021. Doctor permission was obtained and the patient sign a consent form. A hundred and twenty participants of both sexes were randomly selected and categorized into three main groups: psoriasis, ischemic heart disease, and healthy control. The first group includes forty psoriasis patients who have classical psoriatic lesions with a well-demarcated salmon color plaque and silvery. There were 23 male and 17 female psoriatic patients with a median (30.50), age range: 7-71 years. The second group includes patients with well-documented ischemic heart disease diagnosed by a cardiologist. There were 17 male and 23 female cardiovascular diseases patients (control positive) with a median (41.50), age range: 13-70 years. Third group of forty participants represents apparently healthy subjects (control negative). There were 26 males and 14 females with a median (36), age range: 2-68 years as a control group. A total of 3 ml of peripheral whole blood was taken from patients, healthy controls and patients with cardiovascular diseases to be used for ELISA test for TPAI-1, VEGF-A, IL-17 and protein analyzer P54 according to manufacture protocol. The results revealed highly significant changes in the TPAI-1, VEGF-A, IL-17, hs-CRP in psoriatic patients comparing to the healthy group with a median of 2.9 ng/ml, 3552.5 ng/ml, 75.9 ng/ml for IL-17 and 4.55 mg/L, respectively (P-value <0.0001). In the CVD group, there were also highly significant changes in these four parameters comparing to the control negative group with a median of 6.1 ng/ml for TPAI-1, 5434.00 ng/ml for VEGF-A, 76.400 ng/ml for IL-17 and 9.4 mg/L for hs -CRP (p-value <0.0001). Psoriasis severity showed significant effect only on serum IL-17 levels, but no effect on TPAI-1, VEGF-A and hs-CRP. [ABSTRACT FROM AUTHOR] |
